IRIS Institutional Research Information System - OPENBS Open Archive UniBS
il nuovo catalogo dedicato alla raccolta e alla disseminazione della produzione scientifica dell'Università degli Studi di
Brescia, denominato OPENBS. E' possibile cercare pubblicazioni in OPENBS:
- per parola chiave, utilizzando la barra di ricerca situata in alto
- per filtro di ricerca (Autore, Titolo, Riviste), utilizzando il pulsante Sfoglia
- specificando criteri di ricerca con possibilità di aggiungere gradualmente più filtri (Autore, Data, Tipologia,..) che
perfezionino i risultati, utilizzando la finestra Ricerca - per elemento di filtro di ricerca (e.g. per un elemento di Tipologia: contributo su rivista) nella sezione Scopri
EnglishPurpose: To assess vitreous concentrations of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandin E 2 (PGE 2) in patients treated with NSAIDs before vitrectomy for macular pucker. Methods: A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day. NSAIDs and PGE 2 levels were evaluated in vitreous samples collected at the beginning of surgery. Results: Mean (SD) vitreous concentrations of the study drugs were 503.13 (241.1) pg/mL for indomethacin, 302.5 (91.03) pg/mL for bromfenac, and 284.38 (128.2) pg/mL for nepafenac. Mean (SD) vitreous PGE 2 levels were 247.9 (140.9) pg/mL for indomethacin, 322.12 (228.1) pg/mL for bromfenac, 448.8 (261.1) pg/mL for nepafenac, and 1,133 (323.9) pg/mL for placebo. All three NSAIDs reduced vitreous PGE 2 levels to a statistically significant extent, without a significant difference among them. Conclusion: All assessed NSAIDs penetrated the vitreous and lowered basal PGE 2 levels. A greater penetration was associated with pseudophakic eyes. The important inhibition of prostaglandins in the retina may have a clinical effect on the management of inflammatory retina diseases.
| Titolo: | Reduction of vitreous prostaglandin E2 Levels after topical administration of Indomethacin 0.5%, Bromfenac 0.09%, and Nepafenac 0.1% |
| Autori: | |
| Data di pubblicazione: | 2016 |
| Rivista: | |
| Abstract: | Purpose: To assess vitreous concentrations of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandin E 2 (PGE 2) in patients treated with NSAIDs before vitrectomy for macular pucker. Methods: A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day. NSAIDs and PGE 2 levels were evaluated in vitreous samples collected at the beginning of surgery. Results: Mean (SD) vitreous concentrations of the study drugs were 503.13 (241.1) pg/mL for indomethacin, 302.5 (91.03) pg/mL for bromfenac, and 284.38 (128.2) pg/mL for nepafenac. Mean (SD) vitreous PGE 2 levels were 247.9 (140.9) pg/mL for indomethacin, 322.12 (228.1) pg/mL for bromfenac, 448.8 (261.1) pg/mL for nepafenac, and 1,133 (323.9) pg/mL for placebo. All three NSAIDs reduced vitreous PGE 2 levels to a statistically significant extent, without a significant difference among them. Conclusion: All assessed NSAIDs penetrated the vitreous and lowered basal PGE 2 levels. A greater penetration was associated with pseudophakic eyes. The important inhibition of prostaglandins in the retina may have a clinical effect on the management of inflammatory retina diseases. |
| Handle: | http://hdl.handle.net/11379/483221 |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| retina PG vitreous 2016.pdf | PG VITREOUS retina 2016 | Full Text | DRM non definito | Administrator Richiedi una copia |
Copyright © 2021